AstraZeneca PLC (AZN) P/E Ratio History
Historical price-to-earnings valuation from 2000 to 2026
Loading P/E history...
AZN Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 7, 2026, AstraZeneca PLC (AZN) trades at a price-to-earnings ratio of 28.3x, with a stock price of $184.92 and trailing twelve-month earnings per share of $6.66.
The current P/E is 53% below its 5-year average of 60.0x. Over the past five years, AZN's P/E has ranged from a low of 24.8x to a high of 413.8x, placing the current valuation at the 15th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, AZN trades at a 28% premium to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.
The PEG ratio of 1.30 (P/E divided by 191% EPS growth) suggests a fair valuation relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, AZN trades roughly in line with the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our AZN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
AZN P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $151B | 19.5 | - | -4% | |
| $280B | 15.6Lowest | 0.73Best | +8% | |
| $933B | 43.0 | 1.49 | +96% | |
| $115B | 16.4 | - | +178%Best | |
| $363B | 86.5 | - | -1% | |
| $283B | 20.6 | 1.34 | +22% | |
| $106B | 18.4 | - | -7% | |
| $170B | 358.7 | - | -92% | |
| $75B | 17.4 | 2.75 | +8% | |
| $28B | 21.6 | - | -21% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
AZN Historical P/E Data (2000–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | $197.22 | $6.64 | 29.7x | +3% | |
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $175.50 | $6.54 | 26.8x | -7% |
| FY2025 Q3 | $149.50 | $6.02 | 24.8x | -14% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $138.18 | $5.32 | 26.0x | -10% |
| FY2025 Q1 | Sun Mar 30 2025 00:00:00 GM | $147.47 | $4.99 | 29.6x | +2% |
| FY2024 Q4 | $130.00 | $4.52 | 28.8x | -1% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $154.46 | $4.17 | 37.0x | +28% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $156.27 | $4.13 | 37.8x | +31% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $136.96 | $4.06 | 33.7x | +16% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $134.45 | $3.82 | 35.2x | +21% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $135.05 | $3.79 | 35.6x | +23% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $143.90 | $3.96 | 36.3x | +25% |
Average P/E for displayed period: 29.0x
Full AZN Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Should I Buy AZN Right Now?
Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.
See AZN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AZN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AZN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAZN — Frequently Asked Questions
Quick answers to the most common questions about buying AZN stock.
Is AZN stock overvalued or undervalued?
AZN trades at 28.3x P/E, below its 5-year average of 60.0x. At the 15th percentile of historical range, the stock is priced at a discount to its own history.
How does AZN's valuation compare to peers?
AstraZeneca PLC P/E of 28.3x compares to sector median of 22.1x. The premium reflects expected growth above peers.
What is AZN's PEG ratio?
AZN PEG ratio is 1.30. Between 1-2 suggests valuation aligns with growth. Historical P/E data spans 2000-2026.